272 filings
Page 4 of 14
8-K
9tn2dmzstl94027bna3
23 Mar 23
Moleculin Reports Full Year 2022 Financial Results and Provides Pipeline Update
8:20am
8-K
f25l8u
22 Mar 23
Regulation FD Disclosure
4:20pm
8-K
5zv1heo
15 Mar 23
Regulation FD Disclosure
8:30am
8-K
coqp9 up5u6
13 Mar 23
Moleculin Announces it Has No Exposure to Silicon Valley Bank Situation
7:05am
8-K
m7anq1lhewyodgtsdota
9 Mar 23
Regulation FD Disclosure
8:35am
8-K
brpuaq
1 Mar 23
Regulation FD Disclosure
8:45am
8-K
sag5l moy
13 Feb 23
Regulation FD Disclosure
8:11am
8-K
x1jxqfgqliy3
8 Feb 23
Regulation FD Disclosure
5:00pm
8-K
fp9qwsslvkh 0cwl
3 Feb 23
Termination of a Material Definitive Agreement
5:20pm
8-K
yv9x7yahxuarwk3w8z8a
21 Dec 22
Regulation FD Disclosure
8:25am
8-K
vi75p3e3 04
15 Dec 22
Preliminary efficacy updated to 80% overall response rate (ORR) demonstrated in single agent AML trial following database lock
8:37am
8-K
3rhcjpwm9 8vjtsxk
7 Dec 22
Moleculin Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme
8:45am
8-K
xaajhe03tvmp mcel
14 Nov 22
Regulation FD Disclosure
8:00am
8-K
vjx9pl jt5lz
10 Nov 22
Moleculin Reports Third Quarter 2022 Financial Results and Provides Pipeline Update
4:11pm
8-K
lcoz7t
14 Oct 22
Moleculin Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
8:40am
8-K
1jfoeyv lhqr6xbccj
27 Sep 22
Regulation FD Disclosure
8:36am
8-K
k3krbyperhn6u i6
9 Sep 22
Regulation FD Disclosure
4:00pm
8-K
w7wh05
6 Sep 22
Moleculin Receives FDA Orphan Drug Designation of WP1122 for the Treatment of Glioblastoma Multiforme
8:45am
8-K
dkcwcl jobnpj3g6
19 Aug 22
Moleculin Announces Completion of Third Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
8:40am
8-K
onkkwcrc
18 Aug 22
Regulation FD Disclosure
5:06pm